Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
175 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Myelofibrosis - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Myelofibrosis - Pipeline Review, H1 2015', provides an overview of the Myelofibrosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Myelofibrosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Myelofibrosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Myelofibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Myelofibrosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Myelofibrosis Overview 9 Therapeutics Development 10 Pipeline Products for Myelofibrosis - Overview 10 Pipeline Products for Myelofibrosis - Comparative Analysis 11 Myelofibrosis - Therapeutics under Development by Companies 12 Myelofibrosis - Therapeutics under Investigation by Universities/Institutes 15 Myelofibrosis - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Myelofibrosis - Products under Development by Companies 19 Myelofibrosis - Products under Investigation by Universities/Institutes 21 Myelofibrosis - Companies Involved in Therapeutics Development 22 Acceleron Pharma, Inc. 22 Bristol-Myers Squibb Company 23 Celgene Corporation 24 CTI BioPharma Corp. 25 Gilead Sciences, Inc. 26 Incyte Corporation 27 Italfarmaco S.p.A. 28 Johnson & Johnson 29 KaloBios Pharmaceuticals, Inc. 30 MEI Pharma, Inc. 31 Nippon Shinyaku Co., Ltd. 32 Novartis AG 33 Onconova Therapeutics, Inc. 34 Pfizer Inc. 35 PharmaEssentia Corporation 36 Promedior, Inc. 37 Stemline Therapeutics, Inc. 38 Threshold Pharmaceuticals, Inc. 39 Myelofibrosis - Therapeutics Assessment 40 Assessment by Monotherapy Products 40 Assessment by Target 41 Assessment by Mechanism of Action 43 Assessment by Route of Administration 45 Assessment by Molecule Type 47 Drug Profiles 49 BMS-911543 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 buparlisib hydrochloride - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 erismodegib - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 evofosfamide - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 givinostat - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 glasdegib - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 imetelstat sodium - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 INCB-39110 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 KB-004 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 LCL-161 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 momelotinib - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 NS-018 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 pacritinib - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 panobinostat - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 peginterferon alfa-2b - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 pomalidomide - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 pracinostat - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 PRM-151 - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 rigosertib sodium - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 simtuzumab - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 SL-401 - Drug Profile 107 Product Description 107 Mechanism of Action 107 R&D Progress 107 Small Molecules to Inhibit JAK for Oncology and Hematological Disorders - Drug Profile 109 Product Description 109 Mechanism of Action 109 R&D Progress 109 sotatercept - Drug Profile 110 Product Description 110 Mechanism of Action 110 R&D Progress 110 Myelofibrosis - Recent Pipeline Updates 112 Myelofibrosis - Dormant Projects 162 Myelofibrosis - Discontinued Products 163 Myelofibrosis - Product Development Milestones 164 Featured News & Press Releases 164 Dec 09, 2014: CTI BioPharma Announces Presentation of Data Demonstrating Pacritinib Overrides Stromal Mediated Resistance in FLT3-ITD Positive AML Cells 164 Dec 09, 2014: Promedior Presents Positive Phase 2 Data for PRM-151 in Myelofibrosis at ASH Annual Meeting 165 Dec 08, 2014: PRM-151 therapy well tolerated in patients with advanced myelofibrosis 166 Dec 06, 2014: CTI BioPharma Announces Comprehensive Kinome Analysis that Demonstrates Pacritinib Inhibits Kinases Linked to a Spectrum of Blood-Related Cancers 167 Dec 02, 2014: Incyte To Present Data On INCB039110 At at the 2014 American Society of Hematology Annual Meeting 168 Dec 01, 2014: CTI BioPharma Announces Data Presentation at the 56th American Society of Hematology Annual Meeting 169 Nov 06, 2014: Promedior Announces Presentation of Phase 2 Data on PRM-151 in Myelofibrosis at the Upcoming ASH Annual Meeting 170 Nov 03, 2014: Geron Announces Removal of Full Clinical Hold on Imetelstat IND 171 Nov 03, 2014: Promedior Receives Fast Track Designation for PRM-151 for the Treatment of Myelofibrosis 171 Sep 02, 2014: Promedior Receives U.S. Orphan Drug Designation for PRM-151 for the Treatment of Myelofibrosis 172 Appendix 174 Methodology 174 Coverage 174 Secondary Research 174 Primary Research 174 Expert Panel Validation 174 Contact Us 174 Disclaimer 175
List of Tables Number of Products under Development for Myelofibrosis, H1 2015 10 Number of Products under Development for Myelofibrosis - Comparative Analysis, H1 2015 11 Number of Products under Development by Companies, H1 2015 13 Number of Products under Development by Companies, H1 2015 (Contd..1) 14 Number of Products under Investigation by Universities/Institutes, H1 2015 15 Comparative Analysis by Late Stage Development, H1 2015 16 Comparative Analysis by Clinical Stage Development, H1 2015 17 Comparative Analysis by Early Stage Development, H1 2015 18 Products under Development by Companies, H1 2015 19 Products under Development by Companies, H1 2015 (Contd..1) 20 Products under Investigation by Universities/Institutes, H1 2015 21 Myelofibrosis - Pipeline by Acceleron Pharma, Inc., H1 2015 22 Myelofibrosis - Pipeline by Bristol-Myers Squibb Company, H1 2015 23 Myelofibrosis - Pipeline by Celgene Corporation, H1 2015 24 Myelofibrosis - Pipeline by CTI BioPharma Corp., H1 2015 25 Myelofibrosis - Pipeline by Gilead Sciences, Inc., H1 2015 26 Myelofibrosis - Pipeline by Incyte Corporation, H1 2015 27 Myelofibrosis - Pipeline by Italfarmaco S.p.A., H1 2015 28 Myelofibrosis - Pipeline by Johnson & Johnson, H1 2015 29 Myelofibrosis - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2015 30 Myelofibrosis - Pipeline by MEI Pharma, Inc., H1 2015 31 Myelofibrosis - Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 32 Myelofibrosis - Pipeline by Novartis AG, H1 2015 33 Myelofibrosis - Pipeline by Onconova Therapeutics, Inc., H1 2015 34 Myelofibrosis - Pipeline by Pfizer Inc., H1 2015 35 Myelofibrosis - Pipeline by PharmaEssentia Corporation, H1 2015 36 Myelofibrosis - Pipeline by Promedior, Inc., H1 2015 37 Myelofibrosis - Pipeline by Stemline Therapeutics, Inc., H1 2015 38 Myelofibrosis - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 39 Assessment by Monotherapy Products, H1 2015 40 Number of Products by Stage and Target, H1 2015 42 Number of Products by Stage and Mechanism of Action, H1 2015 44 Number of Products by Stage and Route of Administration, H1 2015 46 Number of Products by Stage and Molecule Type, H1 2015 48 Myelofibrosis Therapeutics - Recent Pipeline Updates, H1 2015 112 Myelofibrosis - Dormant Projects, H1 2015 162 Myelofibrosis - Discontinued Products, H1 2015 163
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
